These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 11988366)

  • 1. Environmental risk assessment for new human pharmaceuticals in the European Union according to the draft guideline/discussion paper of January 2001.
    Straub JO
    Toxicol Lett; 2002 May; 131(1-2):137-43. PubMed ID: 11988366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Environmental risk assessment for new human pharmaceuticals in the European Union according to the draft guideline/discussion paper of January 2001.
    Straub JO
    Toxicol Lett; 2002 Oct; 135(3):231-7. PubMed ID: 12270681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of measured and predicted environmental concentrations of selected human pharmaceuticals and personal care products.
    Liebig M; Moltmann JF; Knacker T
    Environ Sci Pollut Res Int; 2006 Mar; 13(2):110-9. PubMed ID: 16612900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Environmental risk assessment of six human pharmaceuticals: are the current environmental risk assessment procedures sufficient for the protection of the aquatic environment?
    Ferrari B; Mons R; Vollat B; Fraysse B; Paxéus N; Lo Giudice R; Pollio A; Garric J
    Environ Toxicol Chem; 2004 May; 23(5):1344-54. PubMed ID: 15180389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined environmental risk assessment for 5-fluorouracil and capecitabine in Europe.
    Straub JO
    Integr Environ Assess Manag; 2010 Jul; 6 Suppl():540-66. PubMed ID: 19958049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Environmental risk assessment of human pharmaceuticals in the European Union: A case study with the β-blocker atenolol.
    Küster A; Alder AC; Escher BI; Duis K; Fenner K; Garric J; Hutchinson TH; Lapen DR; Péry A; Römbke J; Snape J; Ternes T; Topp E; Wehrhan A; Knacker T
    Integr Environ Assess Manag; 2010 Jul; 6 Suppl():514-23. PubMed ID: 19886730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Environmental risk assessment of pharmaceutical drug substances--conceptual considerations.
    Länge R; Dietrich D
    Toxicol Lett; 2002 May; 131(1-2):97-104. PubMed ID: 11988362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The environmental risk assessment of human pharmaceuticals in the overall EU regulatory affairs process.
    Laenge R; Steger-Hartmann T; Schweinfurth H
    Regul Toxicol Pharmacol; 2006 Aug; 45(3):223-8. PubMed ID: 16716476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human pharmaceuticals in surface waters. Implementation of a prioritization methodology and application to the French situation.
    Besse JP; Garric J
    Toxicol Lett; 2008 Jan; 176(2):104-23. PubMed ID: 18077113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Environmental risk assessment for the serotonin re-uptake inhibitor fluoxetine: Case study using the European risk assessment framework.
    Oakes KD; Coors A; Escher BI; Fenner K; Garric J; Gust M; Knacker T; Küster A; Kussatz C; Metcalfe CD; Monteiro S; Moon TW; Mennigen JA; Parrott J; Péry AR; Ramil M; Roennefahrt I; Tarazona JV; Sánchez-Argüello P; Ternes TA; Trudeau VL; Boucard T; Van Der Kraak GJ; Servos MR
    Integr Environ Assess Manag; 2010 Jul; 6 Suppl():524-39. PubMed ID: 20821717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An environmental risk assessment for oseltamivir (Tamiflu) for sewage works and surface waters under seasonal-influenza- and pandemic-use conditions.
    Straub JO
    Ecotoxicol Environ Saf; 2009 Sep; 72(6):1625-34. PubMed ID: 19560203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Environmental risk assessment of medicinal products for human use according to European Commission recommendations.
    Huschek G; Hansen PD; Maurer HH; Krengel D; Kayser A;
    Environ Toxicol; 2004 Jun; 19(3):226-40. PubMed ID: 15101038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranking of concern, based on environmental indexes, for pharmaceutical and personal care products: an application to the Spanish case.
    Ortiz de García S; Pinto GP; García-Encina PA; Irusta Mata RI
    J Environ Manage; 2013 Nov; 129():384-97. PubMed ID: 23995140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hindsight rather than foresight: reality versus the EU draft guideline on pharmaceuticals in the environment.
    O'Brien E; Dietrich DR
    Trends Biotechnol; 2004 Jul; 22(7):326-30. PubMed ID: 15245903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Environmental risk assessment of musk ketone and musk xylene in The Netherlands in accordance with the EU-TGD.
    Tas JW; Balk F; Ford RA; van de Plassche EJ
    Chemosphere; 1997 Dec; 35(12):2973-3002. PubMed ID: 9415982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Environmental risk assessment of zinc in European freshwaters: a critical appraisal.
    Van Sprang PA; Verdonck FA; Van Assche F; Regoli L; De Schamphelaere KA
    Sci Total Environ; 2009 Oct; 407(20):5373-91. PubMed ID: 19631966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Environmental assessment of Norwegian priority pharmaceuticals based on the EMEA guideline.
    Grung M; Källqvist T; Sakshaug S; Skurtveit S; Thomas KV
    Ecotoxicol Environ Saf; 2008 Oct; 71(2):328-40. PubMed ID: 18068226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Environmental risk assessment of ivermectin: A case study.
    Liebig M; Fernandez AA; Blübaum-Gronau E; Boxall A; Brinke M; Carbonell G; Egeler P; Fenner K; Fernandez C; Fink G; Garric J; Halling-Sørensen B; Knacker T; Krogh KA; Küster A; Löffler D; Cots MA; Pope L; Prasse C; Römbke J; Rönnefahrt I; Schneider MK; Schweitzer N; Tarazona JV; Ternes TA; Traunspurger W; Wehrhan A; Duis K
    Integr Environ Assess Manag; 2010 Jul; 6 Suppl():567-87. PubMed ID: 20821718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Environmental Risk Assessment (ERA) of diclofenac and ibuprofen: a public health perspective.
    Gamarra JS; Godoi AF; de Vasconcelos EC; de Souza KM; de Oliveira CM
    Chemosphere; 2015 Feb; 120():462-9. PubMed ID: 25243806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the OECD 314B activated sludge die-away test for assessing the biodegradation of pharmaceuticals.
    Ericson JF
    Environ Sci Technol; 2010 Jan; 44(1):375-81. PubMed ID: 19961217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.